We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Life Sciences

  • September 21, 2018

    PTAB Upholds Alcon Patent For Glaucoma Treatment

    The Patent Trial and Appeal Board on Thursday upheld the validity of an Alcon patent covering the glaucoma treatment Travatan Z, rejecting arguments by generics maker Argentum that the invention was obvious.

  • September 21, 2018

    15 Firms To Lead IPOs Exceeding $1.1B Amid Peak Season

    Fifteen law firms will guide initial public offerings from 13 companies that are expected to raise more than $1.1 billion during the week of Sept. 24, a busy lineup dominated by technology and life sciences firms going public during a sweet spot on the annual IPO calendar.

  • September 21, 2018

    Athenex Gets FDA Compounding Policy Wrong, Amicus Says

    Compounder Athenex Pharma Solutions LLC is wrongly attempting to broaden a U.S. Food and Drug Administration policy governing bulk compounding, and its “gross misinterpretation” must be kept out of Par Pharmaceutical’s suit challenging that policy, an AmerisourceBergen Corp. subsidiary has told a D.C. federal court.

  • September 21, 2018

    Health Hires: DLA Piper, Baker Donelson, Pharma GCs

    DLA Piper has brought in life sciences attorneys from Hogan Lovells and Vinson & Elkins LLP, Baker Donelson Bearman Caldwell & Berkowitz PC has boosted its health care group in Memphis, Tennessee, Aquestive Therapeutic has nabbed the head of Day Pitney LLP's life sciences group and Clearside Biomedical has hired an in-house veteran to lead its legal team.

  • September 21, 2018

    Consumer Seeks Full 3rd Circ. Redo Of Toxic Talc Ruling

    Alleging that the Third Circuit contradicted its own prior rulings and created a split with the Ninth Circuit by dismissing a Johnson & Johnson consumer’s proposed class action over talcum powder as “buyer’s remorse,” the customer’s attorneys on Friday asked for the full court to rehear the case.

  • September 21, 2018

    Allergan, Tribe Sue Pharma Co. Over Restasis Patent

    Allergan PLC and the Saint Regis Mohawk Tribe slapped generic drug manufacturer Amneal Pharmaceuticals with a patent infringement suit over the dry-eye drug Restasis in Delaware federal court on Thursday, even as the fate of related patents for the drug hangs in the balance at the Federal Circuit.

  • September 21, 2018

    Atty Can't Shake $1.76M Suit Over Alleged Consulting Scam

    A Texas federal judge has declined to throw out a suit by a medical device developer accusing a California attorney of scamming it out of $1.76 million, ruling that the court did have jurisdiction over the case.

  • September 21, 2018

    MabVax Stock Actions Stand Amid Pump-And-Dump Claims

    A Delaware vice chancellor on Thursday let stand a series of stock conversions that biotech company MabVax Therapeutics Holdings Inc. had worried were in question due to claims of a “well-planned” and “extensive” pump-and-dump scheme that is the subject of a recent federal lawsuit.

  • September 21, 2018

    Sterigenics Hid Cancer Risk Of Emissions, Ill. Residents Say

    Residents of a Chicago suburb have slapped Sterigenics International Inc. and its private equity owner with a proposed class action in Illinois circuit court that claims the sterilization company has for decades knowingly emitted a highly carcinogenic chemical from a local facility without disclosing the risks.

  • September 21, 2018

    Class Attys Get $35M Of $105M Lidoderm Pay-For-Delay Deal

    A California federal judge has awarded $35 million in attorneys' fees as part of a settlement for end-payors that claimed a group of pharmaceutical companies delayed the release of a generic form of the Lidoderm pain patch.

  • September 21, 2018

    Fosamax MDL Revival Must Be Nixed, US Tells High Court

    The Office of the U.S. Solicitor General has urged the U.S. Supreme Court to overturn a Third Circuit decision reviving multidistrict litigation over Merck Sharp & Dohme Corp.’s alleged failure to warn about a risk of femoral fractures from its osteoporosis drug Fosamax, saying such claims are preempted because regulators rejected the company's proposed warning.

  • September 21, 2018

    Wage-And-Hour Suit Against J&J Headed Back To State Court

    A California federal judge has agreed to send back to state court a wage-and-hour suit brought by a group of former Johnson & Johnson Consumer Inc. workers, finding that the amount of money in controversy fell short of the threshold necessary for the federal court to hear the case.

  • September 20, 2018

    New MDL Needed For 'Opioid Babies,' Attys Say

    Attorneys for “opioid babies” whose mothers used prescription narcotics argued on Thursday for new multidistrict litigation focused on the infants, citing “grave concerns” that an existing MDL over the opioid crisis is woefully deficient.

  • September 20, 2018

    Correction: Attys Sanctioned $655K After $645M Medical Device Row Loss

    An Ohio federal judge ordered Cavitch Familo & Durkin Co. and three of its attorneys to pay more than $655,000 in sanctions Wednesday for its discovery abuses while representing Healthcare Essentials Inc., which was ordered to pay medical device maker KCI USA Inc. $645 million in trebled damages earlier this month for stealing and rebranding KCI’s product.

  • September 20, 2018

    Counsel Needs 'Backup' For Payment In $4.75M Vertex Deal

    A Massachusetts federal magistrate judge has told Anderson & Wanca and Swartz & Swartz PC that they failed to submit sufficient evidence of the firms' expenses that went into striking a $4.75 million deal with Vertex Pharmaceuticals Inc. to end class action allegations of unsolicited faxes.

  • September 20, 2018

    7th Circ. Will Not Rehear Suit Against GSK Over Atty's Suicide

    The Seventh Circuit on Thursday refused to reconsider its decision to overturn a $3 million verdict blaming GlaxoSmithKline for the suicide of a Reed Smith partner who had been taking a generic version of its Paxil drug.

  • September 20, 2018

    FTC Settles With ‘IV Cocktail’ Seller Over Health Claims

    The Federal Trade Commission told a company selling intravenous therapy products to cease marketing its iV Cocktails as alternative treatments for serious diseases without backing those claims with scientific and medical testing, according to a consent order filed Thursday.

  • September 20, 2018

    Houston Pill Mill Doc, Clinic Chief Each Get 35 Years In Prison

    A Houston doctor and the owner of the pain management clinic where she worked were each sentenced to 35 years in prison by a federal judge in Texas on Thursday for their roles in running what prosecutors called the “most prolific hydrocodone pill mill in Houston.”

  • September 20, 2018

    J&J Can't Escape Calif. Talc Warning Label Suit

    A California federal judge has rebuffed Johnson & Johnson's bid to dismiss a suit alleging it violates state warning label and false advertising laws by selling asbestos-contaminated talcum powder products, writing the consumer products giant was "simply demanding more" detail than is necessary in a complaint.

  • September 20, 2018

    Purdue Pharma Must Face N.H.'s Suit Over Opioid Marketing

    A New Hampshire court has given the state the go-ahead to pursue its claims that Purdue Pharma pushed the opioid OxyContin with a deceptive marketing campaign that overstated the drug’s benefits and underplayed its risks.

Expert Analysis

  • Cloud Computing Clearly The Future For Small Firms

    Holly Urban

    While in-house technology investments on the scale and complexity needed to compete with large firms remain cost prohibitive for small and midsize law firms, cloud-based services offer significant cost savings and productivity gains with little to no capital investment, says Holly Urban of Effortless Legal LLC.

  • Telemedicine — The Next Frontier For DOJ Scrutiny?

    andre.jpg

    CVS is the first major drugstore company to offer customers the option to use their smartphone to “see” a doctor. With the U.S. Department of Justice affording more resources to health care fraud prosecutions, telemedicine services are certain to attract the scrutiny of investigators, say Lionel André and Michelle Bradford of Murphy & McGonigle PC.

  • Leveraging Today's Lateral Associate Market

    Darin Morgan

    With the Milbank/Cravath pay scale once again equalizing compensation at many Am Law 100 firms, there is even more pressure for firms to differentiate themselves to top lateral associate candidates. This presents strategic considerations for both law firms and lateral candidates throughout the recruitment process, says Darin Morgan of Major Lindsey & Africa.

  • 'One A Day' Will Not Keep Plaintiffs Away

    Robert Guite

    In a ruling earlier this month concerning Bayer's "One A Day" vitamin gummies, a California state appeals court clarified how the defendant cannot rely on the fine print to escape a mislabeling claim at the pleadings stage. In doing so, the court appears to have laid a road map for how to defeat class certification in such cases, say Robert Guite and Jay Ramsey of Sheppard Mullin Richter & Hampton LLP.

  • Q&A

    Back To School: Stanford's Jeff Fisher Talks Supreme Court

    Jeffrey Fisher

    In this series featuring law school luminaries, Stanford Law School professor Jeffrey Fisher discusses his motivation for teaching, arguing before the U.S. Supreme Court and what the court might look like if Judge Brett Kavanaugh is confirmed.

  • Genetic Data Holds Opportunities And Risks For Litigants

    Kirk Hartley

    A recently published research paper concludes that a significant proportion of patients with malignant mesotheliomas carry inherited mutations in cancer-associated genes. Well-informed lawyers on both sides of the aisle can effectively use such data to materially alter the outcome of cases, say Kirk Hartley and David Schwartz of ToxicoGenomica.

  • Biotech Cos. Must Respect Coexisting Gene Editing Patents

    Tyler Cho

    The Federal Circuit's decision in the gene editing technology battle between the University of California and the Broad Institute provides that the two parties' patents can coexist. Biotech companies using this technology should seek licenses from both UC and the Broad Institute, say attorneys at Faegre Baker Daniels LLP.

  • Opinion

    Orexigen Decision At Odds With High Court Jurisprudence

    Douglas Greene

    The Ninth Circuit's decision last month in Khoja v. Orexigen Therapeutics — placing constraints on the record a court may consider in deciding falsity and scienter under the securities laws — countermands the U.S. Supreme Court’s direction to courts in Omnicare and Tellabs, say attorneys with BakerHostetler.

  • What Manufacturers Should Know About Triclosan Findings

    Doug Pfeifer

    A recent study suggests that triclosan, a common antibacterial agent, can promote colonic inflammation and cancer in mice when ingested at what the authors deem normal human exposure levels from using certain consumer products. But this research is unlikely to find its way into the courtroom, say Douglas Pfeifer and Richard Morgan of Bowman and Brooke LLP and Brent Kerger of Exponent Inc.

  • Calif.'s New Rules For Lawyers Move Closer To ABA Model

    Mark Loeterman

    The first comprehensive overhaul of California's Rules of Professional Conduct in nearly 30 years becomes operational on Nov. 1. Some of the new rules mirror the model language used by the American Bar Association, but many continue to reflect California’s unique approach to certain ethical questions, says Mark Loeterman of Signature Resolution LLC.